This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
AURKB / Aurora kinase B · IHC design guide
Design Immunohistochemistry for AURKB
Plan paraffin-section AURKB IHC around nuclear staining, most abundant in lymphoid immune cells and the gastrointestinal tract (HPA tissue IHC). A catalog antibody has a 1:50 IHC example in human tonsil (datasheet: M00762-1); interpret staining cautiously because presumed off-target binding was observed (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
AURKB Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in tissue (HPA tissue IHC) | |
| Staining pattern | Nuclear signal is most abundant in lymphoid immune and GI cells (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet M00762-1) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Presumed off-target staining warrants cautious scoring (HPA tissue IHC) | |
| Regulation | Higher in S/G2-M and cancer M phase (UniProt) | |
| Isoform / epitope | 5 isoforms; verify epitope coverage across variants (UniProt) |
Section 1
Recommended AURKB IHC & IF Protocols
Compare the catalog antibody protocol (datasheet: M00762-1) with 3 published AURKB IHC protocols (PMC7053608; PMC7960835; PMC10023558).
| Sample | Paraffin-embedded human bladder urothelial carcinoma tissue; fixative not specified (datasheet M00762-1) |
| Fixation | Image fixative and duration unreported (datasheet M00762-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet M00762-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet M00762-1) |
| Primary antibody | Rabbit monoclonal (clone FA-1) anti-AURKB, 1:50 (datasheet M00762-1) |
| Primary incubation | Overnight at 4 °C (datasheet M00762-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet M00762-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | AURKB-positive staining in endocrine cells of appendix (HPA tissue IHC: High). HPA tissue profile: Nuclear expression in several tissues, most abundant in immune cells of lymphoid tissues and gastrointestinal tract. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 for the catalog antibody (datasheet: M00762-1); the xenograft study used citric acid at pH 6.0 (PMC10023558).
Section 2
What Is the Expected AURKB Staining Pattern?
AURKB is mainly nuclear in tissue IHC, with staining expected in selected lymphoid and gastrointestinal cells (HPA tissue IHC). During mitosis it moves from chromosomes and centromeres to the spindle midzone and midbody (UniProt Q96GD4). It has no transmembrane segment (UniProt Q96GD4 topology). HPA rates tissue IHC reliability Enhanced, while reporting medium staining–RNA consistency and presumed off-target binding that was disregarded (HPA tissue IHC).
| Distinct nuclear staining in appendix, colon, duodenum, rectum or small-intestine endocrine cells. | This fits the cell types scored High by HPA; interpret the signal in identified cells, since a High score for endocrine cells does not make every cell in that tissue an expected positive (HPA tissue IHC). |
| Nuclear signal in hematopoietic cells of bone marrow or non-germinal-center cells of lymph node. | Both cell populations are scored Medium, providing additional expected-positive patterns. Compare the named cell population and compartment before judging staining strength (HPA tissue IHC). |
| Strong membrane staining or uniform cytoplasmic staining without a convincing nuclear pattern. | That distribution does not match the predominant tissue nuclear profile or a protein lacking a transmembrane segment. Check morphology and detection controls before assigning it to AURKB; mitotic spindle or midbody signal has a separate phase-dependent basis (HPA tissue IHC; UniProt Q96GD4 topology and subcellular location). |
| Prominent staining in adipocytes or heart-muscle cardiomyocytes, particularly with little expected-positive nuclear staining. | HPA scores those specific cell populations Not detected. Treat the mismatch as possible nonspecific antibody binding or detection activity, rather than evidence that the whole tissue is AURKB-negative; HPA also reports presumed off-target binding (HPA tissue IHC; standard IHC practice). |
| Diffuse color across nuclei, cytoplasm and tissue edges, or no signal in an expected-positive cell population. | Diffuse color limits compartment scoring and can reflect background from the staining workflow. Absence of signal in a sampled High-scoring endocrine population calls for a control and assay check before concluding that AURKB is absent from the specimen (HPA tissue IHC; standard IHC practice). |
💡Expected AURKB appearanceCall the result consistent when identified gastrointestinal endocrine cells show clear nuclear staining, scored High in HPA; diffuse color or dominant membrane staining is suspect (HPA tissue IHC; UniProt Q96GD4 topology).
| Cell identity and sampling | HPA scores gastrointestinal endocrine cells High, bone-marrow hematopoietic cells and lymph-node non-germinal-center cells Medium, and skin basal-layer cells Low; assess the named cells rather than averaging an entire section (HPA tissue IHC). |
| Mitotic phase | AURKB occupies chromosome arms and inner centromeres from prophase through metaphase, then the spindle midzone and midbody from anaphase through cytokinesis. A static section can therefore show different compartments in different mitotic cells (UniProt Q96GD4 subcellular location). |
| Antibody evidence | HPA lists CAB005862 as IHC Enhanced and HPA037708 as ICC Supported; those statuses apply to different assays. Tissue IHC also carries a medium staining–RNA consistency caveat and a note about disregarded presumed off-target binding (HPA antibodies; HPA tissue IHC). |
| IF/ICC Q&A: What location should fluorescence show? | Mainly nucleoplasm, with supported midbody and uncertain kinetochore localization in HPA ICC-IF; phase-dependent chromosome and spindle locations are also described by UniProt. This IF/ICC observation does not substitute for tissue IHC validation (HPA subcellular; UniProt Q96GD4; HPA antibodies). |
| Isoforms and epitope coverage | UniProt lists five AURKB isoforms, but the supplied record gives no antibody epitope or isoform-specific detection result. Do not infer which isoforms contribute to tissue staining (UniProt Q96GD4 isoforms). |
| Situation | Likely cause | Next action |
|---|---|---|
| No nuclear signal in sampled gastrointestinal endocrine cells. | The selected cells are HPA High, so an empty expected-positive field may reflect tissue sampling or an unsuccessful staining run; HPA does not establish which step failed (HPA tissue IHC; standard IHC practice). | Confirm the endocrine cells are present and review an appropriate positive control, antibody dilution, antigen-retrieval run and detection reagents using the validated IHC workflow (standard IHC practice). |
| Signal is chiefly membranous or broadly cytoplasmic. | This conflicts with the HPA nuclear tissue profile and UniProt's lack of a transmembrane segment, although localized spindle or midbody staining may occur in mitotic cells (HPA tissue IHC; UniProt Q96GD4). | Identify mitotic figures and recheck the nuclear counterstain; compare the pattern with an expected-positive section and evaluate nonspecific detection if the mismatch persists (standard IHC practice). |
| Adipocytes or cardiomyocytes appear strongly positive. | HPA reports these cell types as Not detected and notes presumed off-target binding in its tissue assessment (HPA tissue IHC). | Check cell identification and inspect a no-primary control for endogenous or reagent-driven color; interpret residual staining cautiously against HPA's cell-specific reference (standard IHC practice; HPA tissue IHC). |
| Diffuse chromogen obscures cell boundaries or nuclei. | Excess background can prevent reliable localization or scoring; its specific source cannot be assigned from the AURKB evidence supplied here (standard IHC practice). | Review the no-primary control, blocking, washes and detection development; repeat with a clean counterstain that permits nuclear assessment (standard IHC practice). |
| Only scattered cells stain in a field expected to contain AURKB. | AURKB expression varies with cell cycle, while HPA levels describe named cell populations rather than every cell in a section (UniProt Q96GD4 tissue specificity; HPA tissue IHC). | Record the stained cell type and compartment, inspect additional representative fields, and compare with HPA's cell-specific levels before calling the result unexpectedly weak (HPA tissue IHC; standard IHC practice). |
| The IHC result is disputed using an ICC-IF image. | HPA gives separate antibody statuses for IHC and ICC, and its ICC-IF summary includes a kinetochore location marked uncertain (HPA antibodies; HPA subcellular). | Judge tissue IHC against its tissue and antibody evidence, with a matched positive section and detection controls; use ICC-IF localization as context for mitotic structures (HPA tissue IHC; HPA antibodies; standard IHC practice). |
Experiment evidence
IHC & IF images showing AURKB staining
M00762-1 · IHCIHC analysis of AURKB using anti-AURKB antibody (M00762-1). AURKB was detected in a paraffin-embedded section of human bladder urothelial ca
M00762-1 · IHCIHC analysis of AURKB using anti-AURKB antibody (M00762-1). AURKB was detected in a paraffin-embedded section of human tonsil tissue. Heat m
A00762T232 · IHCImmunohistochemistry analysis of paraffin-embedded human liver carcinoma, using AurB (Phospho-Thr232) Antibody. The picture on the right is
A00762T232 · IFImmunofluorescence analysis of HepG2 cells, using AurB (Phospho-Thr232) Antibody. The picture on the right is blocked with the phospho pepti
M00762-5 · IHCHuman tonsil was stained with anti-Aurora B rabbit antibody
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000178999-AURKB/tissue/cerebral+cortex#imid_1761140
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000178999-AURKB/tissue/colon#imid_1761066
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000178999-AURKB/tissue/liver#imid_1761075
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000178999-AURKB/tissue/kidney#imid_1761068
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA037708; green = AURKB, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA037708; green = AURKB, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for AURKB IHC & IF
🧪Run colon first and confirm staining in its endocrine cells (HPA: High in colon endocrine cells). Use adipose tissue adipocytes as the negative tissue (HPA: Not detected in adipocytes); on the colon slide, treat non-endocrine cells as internal negative comparators only if they show no specific staining, since their status is not established by the supplied HPA row (HPA: High in colon endocrine cells).
Positive control tissue: Appendix (Endocrine cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show AURKB in A-431, HEK293, U2OS, ASC52telo, RPTEC/TERT1, hTERT-RPE1 (serum starved), KOLF2.1J, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include no-primary (secondary-only) and host-species- and immunoglobulin-class-matched rabbit isotype controls, plus AURKB-knockout material as a biological negative if available (catalog tissue-IHC caption: rabbit anti-AURKB; standard IHC practice). Quench endogenous peroxidase before HRP/DAB detection and check the colon section for residual background (catalog tissue-IHC caption: HRP/DAB; standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected M00762-1 tissue-IHC caption leaves the fixative unreported (catalog tissue-IHC caption: fixative not stated). That caption documents heat retrieval in EDTA at pH 8.0 for a paraffin section, but does not establish that retrieval is essential for all specimens (catalog tissue-IHC caption: EDTA heat retrieval). The supplied evidence does not establish that frozen sections or IF are easier; assess colon background during optimization, including endogenous peroxidase with HRP/DAB detection (catalog tissue-IHC caption: HRP/DAB; standard IHC practice).
HPA tissue IHC evidence for AURKB
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Presumed off target binding observed and disregarded.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Endocrine cells | High | Protein (IHC) | HPA → |
| Colon | Endocrine cells | High | Protein (IHC) | HPA → |
| Duodenum | Endocrine cells | High | Protein (IHC) | HPA → |
| Rectum | Endocrine cells | High | Protein (IHC) | HPA → |
| Skin | Cells in basal layer | Low | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Cervix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced AURKB IHC Tips
AURKB staining depends on cell cycle stage and compartment. Use the antibody’s documented paraffin-section conditions as the starting point, then assess morphology and controls.
How should I retrieve AURKB when paraffin-section staining is weak?
Start with heat-mediated retrieval in EDTA at pH 8.0 (datasheet M00762-1). This is the retrieval used for the catalog antibody in a paraffin-embedded human bladder urothelial carcinoma section (caption M00762-1). If staining remains weak, first check section adhesion, retrieval heating, and whether the primary incubation matched 1:50 overnight at 4°C (caption M00762-1; standard IHC practice). Compare any adjusted retrieval condition with the documented condition on adjacent sections, because stronger chromogen alone does not establish specific staining (standard IHC practice). Judge improvement by distinct staining in mitotic compartments, while checking for diffuse staining and damaged morphology (UniProt Q96GD4 subcellular; standard IHC practice).
Could fixation explain weak or uneven AURKB staining in my sections?
The selected IHC image documents a paraffin-embedded section but does not state its fixative or fixation duration (caption M00762-1). Target-specific fixation sensitivity is therefore unknown; do not assign a weak result to a particular fixative without a controlled comparison (caption M00762-1; standard IHC practice). Record the actual fixative, fixation interval, processing history, section age, and retrieval run for each specimen before comparing staining (standard IHC practice). Run sections with different processing histories together using EDTA at pH 8.0 and the same detection settings (datasheet M00762-1; standard IHC practice). Interpret differences alongside preserved nuclear and mitotic morphology, since processing variation can complicate an IHC comparison (standard IHC practice).
Why does AURKB appear nuclear in some cells but confined to mitotic structures in others?
AURKB moves from chromosome arms and inner centromeres in prophase through metaphase to the spindle midzone and midbody during anaphase through cytokinesis (UniProt Q96GD4 subcellular). HPA also reports mainly nucleoplasmic localisation, with supported midbody localisation and uncertain kinetochore localisation (HPA subcellular). In chromogenic sections, identify mitotic figures and score their chromosome-associated staining separately from staining in morphologically nonmitotic nuclei (UniProt Q96GD4 subcellular; standard IHC practice). A small number of strongly stained dividing cells can coexist with a broader nuclear pattern; document both patterns instead of collapsing them into one intensity score (HPA tissue IHC; standard IHC practice). Check that apparent midbody staining lies within an identifiable late mitotic cell before assigning that compartment (UniProt Q96GD4 subcellular; standard IHC practice).
Can this IHC antibody distinguish AURKB isoforms or phosphorylation states?
The record lists 5 AURKB isoforms and a protein kinase domain at residues 77–327 (UniProt Q96GD4 isoforms; UniProt Q96GD4 domains). It also lists modified residues, including phosphothreonine 35 and phosphoserine 227, without establishing that this antibody recognises either modification (UniProt Q96GD4 modified residues; caption M00762-1). The supplied IHC caption gives staining conditions but does not identify the recognised epitope or establish isoform or phosphorylation specificity (caption M00762-1). Report staining as AURKB immunoreactivity rather than as a particular isoform or activated form unless separate validation supports that assignment (standard IHC practice). When results conflict with expected localisation, compare an independent epitope reagent and appropriate controls before interpreting the difference biologically (standard IHC practice).
How could IF help investigate an ambiguous AURKB IHC pattern?
Treat IF as a separate validation experiment; the selected antibody’s supplied tissue evidence describes chromogenic staining of a paraffin section (caption M00762-1). Multiplex AURKB with a marker identifying the cell population under investigation, such as colon endocrine cells or lymphoid-tissue immune cells where AURKB staining is reported (HPA tissue IHC; standard IF practice). Choose a spectrally separated, preferably far-red fluorophore after checking the specimen’s autofluorescence with an unstained control (standard IF practice). Because AURKB is intracellular and has no transmembrane segment, use a controlled permeabilisation step appropriate for access to nuclear and mitotic structures (UniProt Q96GD4 topology; UniProt Q96GD4 subcellular; standard IF practice). Compare compartment patterns with the IHC section, without treating an IF result as proof of identical antibody performance across methods (standard IHC/IF practice).
What should I change when AURKB DAB staining looks diffuse or widespread?
First compare a no-primary control and a matched negative tissue area to separate detection background from candidate AURKB staining (standard IHC practice). The documented section used 10% goat serum, primary antibody at 1:50 overnight at 4°C, and an anti-rabbit secondary for 30 minutes at 37°C (caption M00762-1). Check peroxidase blocking, washing, and DAB development as general chromogenic workflow steps, then adjust one variable at a time (standard IHC practice). HPA reports presumed off-target binding despite enhanced tissue-IHC reliability, so diffuse staining deserves an independent specificity check (HPA tissue IHC). Retain staining that tracks plausible nuclear or mitotic compartments and excludes obvious tissue-edge deposits (UniProt Q96GD4 subcellular; standard IHC practice).
How should I quantify AURKB across sections with different mitotic activity? ⚠ ANSWER MARKED FOR VERIFICATION
Define the scored cell population and compartment before analysis, then record the percentage of positive cells and staining intensity or calculate an H-score (standard IHC practice). Count chromosome-associated mitotic figures separately, reporting their positive density per mm² of evaluable tissue when that endpoint fits the question (UniProt Q96GD4 subcellular; standard IHC practice). Normalise cell-based positivity to the number of evaluable cells of that type, and mitotic positivity to the number of identified mitoses when comparing mitotic staining (standard IHC practice). Exclude necrotic, folded, and edge-affected regions by a rule set before scoring (standard IHC practice). Keep retrieval, imaging, and threshold settings consistent across sections, and report the scoring denominator with each result (standard IHC practice).
How can I distinguish genuine AURKB staining from section artefacts?
Look for staining in a plausible compartment: nucleoplasm or identifiable mitotic chromosomes, centromeres, spindle midzone, or midbody (HPA subcellular; UniProt Q96GD4 subcellular). Compare the stained cell type with the specimen context; HPA describes prominent nuclear expression in immune cells of lymphoid tissues and the gastrointestinal tract (HPA tissue IHC). Treat staining confined to section edges, necrotic areas, or disrupted tissue as suspect, and inspect a no-primary control for endogenous peroxidase or detection deposits (standard IHC practice). HPA’s enhanced reliability designation still notes presumed off-target binding, so agreement with expected localisation alone cannot establish antibody specificity (HPA tissue IHC). Resolve a consequential discrepancy with an independent antibody or another orthogonal measurement before drawing a biological conclusion (standard IHC practice).
Boster reagents
Best AURKB / Aurora kinase B IHC Antibodies
IHC images show AURKB staining in human bladder urothelial carcinoma, liver carcinoma and tonsil (catalog IHC captions); an IF image shows HepG2 cells (A00762T232 IF caption).
Real IHC data
Anti-Aurora B AURKB Rabbit Monoclonal Antibody
Cat # M00762-1
Real IHC data
Anti-Phospho-ARK-2 (T232) AURKB Antibody
Cat # A00762T232
Real IHC data
Anti-Aurora B Rabbit Monoclonal Antibody
Cat # M00762-5
M00762-1 has paraffin-section IHC images from human bladder urothelial carcinoma and tonsil (M00762-1 IHC captions); A00762T232 has a paraffin-section IHC image from human liver carcinoma (A00762T232 IHC caption). M00762-5 has a human tonsil IHC image (M00762-5 IHC caption).
Which to pick: For tissue IHC, choose M00762-1 when its documented EDTA pH 8.0 retrieval and 1:50 dilution fit your paraffin sections (M00762-1 IHC caption); the caption does not report the fixative. For IF/ICC, M00762-1 lists both applications (M00762-1 catalog applications); A00762T232 lists IF and has a HepG2 IF image with phospho-peptide blocking (A00762T232 catalog applications and IF caption). For cross-species work, A00762T232 lists human, monkey, mouse and rat reactivity, although its tissue IHC image shows only human liver carcinoma in a paraffin section and does not report the fixative (A00762T232 catalog reactivity and IHC caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q96GD4 (AURKB_HUMAN, Aurora kinase B).
- Human Protein Atlas. AURKB tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. AURKB subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the kinetochore and midbody..
- Human Protein Atlas. AURKB antibody validation summary (2 antibodies).
- AURKB promotes gastric cancer progression via activation of CCND1 expression. Aging 2020 — PMC7053608.
- Gene expression changes are age-dependent and lobe-specific in the brown Norway rat model of prostatic hyperplasia. The Prostate 2009 — PMC2732361.
- Aurora Kinase B Expression, Its Regulation and Therapeutic Targeting in Human Retinoblastoma. Investigative ophthalmology & visual science 2021 — PMC7960835.
- Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening. Prostate cancer and prostatic diseases 2023 — PMC10023558.
- PubMed PMID:9514916 — UniProt-cited evidence.
- PubMed PMID:9809983 — UniProt-cited evidence.
- PubMed PMID:9858806 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for AURKB (Aurora kinase B). Expected localisation Nuclear staining in tissue (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet M00762-1). Validated IHC antibody: M00762-1 at 1:50 (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Endocrine cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human bladder urothelial carcinoma tissue; fixative not specified (datasheet M00762-1); 2. Fixation: Image fixative and duration unreported (datasheet M00762-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet M00762-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet M00762-1); 8. Primary antibody: Rabbit monoclonal (clone FA-1) anti-AURKB, 1:50 (datasheet M00762-1); 9. Primary incubation: Overnight at 4 °C (datasheet M00762-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Presumed off-target staining warrants cautious scoring (HPA tissue IHC); Isoform / epitope: 5 isoforms; verify epitope coverage across variants (UniProt); Regulation: Higher in S/G2-M and cancer M phase (UniProt). Evidence: UniProt Q96GD4, HPA tissue IHC · Enhanced, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet M00762-1, PMC7053608, PMC7960835. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/AURKB/immunohistochemistry-ihc-guide.